INmune Bio (INMB) to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, will host a conference call on Monday, June 30 beginning at 8:00am EDT to present top line data from the Phase 2 MINDFuL trial in early Alzheimer’s Disease.

MINDFuL Results Call Information:

To participate in this event, dial approximately at least 10 minutes before the beginning of the call or use the webcast link below. Please ask for the INmune Bio MINDFuL Conference Call when reaching the operator.

Date: June 30, 2025

Time: 8:00 AM Eastern Time

Participant Dial-in: +1-800-267-6316 Participant Dial-in (international): +1-203-518-9783

You May Also Be Interested In

• EU approves AbbVie's Maviret for acute hepatitis C treatment
• Western Midstream prices $700M in senior notes due 2036
• Premier Graphene anticipates first profitable quarter after Mexico military contracts